LOS ANGELES, CA / ACCESSWIRE / August 5, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between September 16, 2019 and June 29, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before September 14, 2020.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Verrica's proprietary applicator for VP-102 posed safety risks to patients if the instructions were not followed exactly. Based on this risk, the Company built additional user features into the applicator. The applicator change would, in turn, require additional testing and supportive data. This additional work was likely to delay the regulatory approval of VP-102. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Verrica, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm